Showing 1 posts of 1 posts found.

NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer

August 7, 2019
Research and Development, Sales and Marketing Cancer, NCIE, NHS, Nerlynx, Pierre Fabre, UK, breast cancer

Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human …

Latest content